Physician profile
Darshak Karia
NPI 1033170097
$296,030.62
in general payments reported to CMS, 2019-2025
21 companies · $17K in 2025
The $17K reported for 2025 was more than what 83% of Advanced Heart Failure and Transplant Cardiology providers received nationally (typical 2025 total: $1,046).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30K · 2020: $20K · 2021: $45K · 2022: $117K · 2023: $55K · 2024: $12K · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $58K · Travel and Lodging: $18K · Food and Beverage: $5,093 · Consulting Fee: $2,725.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $58,150.00 |
| Travel and Lodging | $17,650.88 |
| Food and Beverage | $5,092.52 |
| Consulting Fee | $2,725.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $144,141.16 | 2021-2025 | Verquvo, Winrevair |
| Abbott Laboratories | $52,935.07 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems, 2nd Gen Centrimag Primary Console |
| Astrazeneca Pharmaceuticals Lp | $37,522.59 | 2020-2024 | Farxiga, Wainua |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21,013.94 | 2022-2023 | Jardiance |
| Alnylam Pharmaceuticals INC. | $15,870.84 | 2019-2025 | Amvuttra, Onpattro |
| Novartis Pharmaceuticals Corporation | $11,384.76 | 2019-2024 | |
| Lilly USA, LLC | $7,131.60 | 2022-2023 | Jardiance |
| Actelion Pharmaceuticals US, INC. | $4,676.20 | 2019-2024 | Opsumit, Uptravi |
| Abiomed | $363.29 | 2019-2023 | Impella |
| Cvrx, INC. | $362.39 | 2022-2025 | Barostim Neo System |
| E.R. Squibb & Sons, L.L.C. | $120.81 | 2022-2025 | Eliquis, Camzyos |
| Biotronik INC. | $115.38 | 2019 | |
| Pfizer INC. | $64.82 | 2021-2023 | |
| Boston Scientific Corporation | $63.37 | 2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $55.45 | 2019-2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $54.95 | 2023-2024 | Inpefa |
| Livanova USA, INC. | $51.85 | 2021 | |
| Scpharmaceuticals INC. | $45.40 | 2023-2024 | |
| Edwards Lifesciences Corporation | $36.90 | 2025 | |
| Medtronic Vascular, INC. | $19.85 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darshak Karia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.